Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
Recruiting · NCT07045935 · Registry updated 2025-09-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment | Neoplasms by Histologic Type, Neoplasms by Site, Pituitary Neoplasms, adenoma, brain disorder, central nervous system disorder, endocrine system disorder, epithelial neoplasm, hyperpituitarism, hyperprolactinemia, hypothalamic disorder, malignant endocrine neoplasm, neoplasm, nervous system disorder, pituitary gland disorder, prolactin deficiency, isolated, prolactin-producing pituitary gland adenoma | Recruiting | Phase 4 | 2025-09-23 | NCT07045935 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University Hospital, Basel, Switzerland | 243 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Hospital Basel, Dept. of Endocrinology, Metabolism & Diabetes | Basel | Switzerland | 1 |